Anti-Human DLL4 Recombinant Antibody(Demcizumab)
-
产品编号
YR1276
-
别名
科研级 Demcizumab ( 登赛珠单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab
-
规格
- 1mg
- 5mg
| Catalog Number | YR1276 |
| Alias | 科研级 Demcizumab ( 登赛珠单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab |
| Size | 1mg, 5mg |
| Molecular Name | Demcizumab |
| CAS Number | 1243262-17-0 |
| Target | DLL4[Homo sapiens] |
| Host | Mouse |
| Antibody Isotype | IgG2 Kappa |
| Clonity | Monoclonal |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Formulation | PBS, pH7.5 |
| Shipping Condition | Shipped on ice packs. |
| Background | Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene. |
| Application | ELISA, FCM, IP, FuncS, IF, Neut, WB |
| Remarks | This product is for research use only. |
0